Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Tryptamine Therapeutics ( (AU:TYP) ) has shared an announcement.
Tryptamine Therapeutics Limited announced its participation in the Biotech Showcase 2025 in San Francisco, providing the company with an opportunity to connect directly with investors managing over US$400 billion in capital and strategic partners in the life sciences sector. This presentation is expected to bolster Tryp’s position in the industry by showcasing its progress and potential in developing psilocin-based treatments, potentially enhancing its market presence and attracting stakeholder interest.
More about Tryptamine Therapeutics
Tryptamine Therapeutics Limited is a clinical-stage biopharmaceutical company that focuses on developing proprietary formulations of psilocin combined with psychotherapy to address diseases with unmet medical needs. The company’s leading product, TRP-8803, is an innovative IV-infused psilocin formulation that aims to enhance the neuroplastic benefits of psilocybin. Tryp has completed clinical trials for binge eating disorder and fibromyalgia, and is conducting trials for irritable bowel syndrome.
YTD Price Performance: -5.26%
Average Trading Volume: 4,023,763
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$47.23M
See more data about TYP stock on TipRanks’ Stock Analysis page.
